Eric Amante

Golimumab, a human anti–tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate‐naive patients with active rheumatoid arthritis: Twenty‐four–week results of a phase III, multicenter, randomized, double‐blind, placebo‐controlled study of golimumab before methotrexate as first‐line therapy for early‐onset rheumatoid arthritis

Paul Emery, Roy Fleischmann, Larry W. Moreland et al. · Arthritis & Rheumatism · 2009 · 396 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis

Brad H. Rovin, Neil Solomons, William F. Pendergraft et al. · Kidney International · 2018 · 304 citations

Medicine, Nephrology, Pharmacology +8

Efficacy and Safety of Subcutaneous Golimumab in Methotrexate‐Naive Patients With Rheumatoid Arthritis: Five‐Year Results of a Randomized Clinical Trial

Paul Emery, Roy Fleischmann, Ingrid Strusberg et al. · Arthritis Care & Research · 2015 · 42 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +10

Golimumab, a Human Anti–Tumor Necrosis Factor Monoclonal Antibody, Injected Subcutaneously Every 4 Weeks in Patients With Active Rheumatoid Arthritis Who Had Never Taken Methotrexate: 1‐Year and 2‐Year Clinical, Radiologic, and Physical Function Findings of a Phase III, Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Study

Paul Emery, Roy Fleischmann, Mittie K. Doyle et al. · Arthritis Care & Research · 2013 · 39 citations

Medicine, Pharmacology, Pharmacotherapy +15